TREatment With Beta-blockers After myOcardial Infarction withOut Reduced Ejection fracTion"

Phase 4

Completed

• Conditions: Myocardial Infarction
• Interventions: Drug: Beta blocker

• Registration Number: NCT03596385
• Lead Sponsor: Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III

Brief Summary

REBOOT clinical trial will study whether long-term maintenance beta-blockers therapy results in a clinical benefit after heart attack without reduced left ventricular function. Half of the participants will be randomized to receive long-term beta-blocker therapy and the other half to no beta-blocker therapy after hospital discharge. All patients will be followed up for up to 5 years to determine the occurrence of adverse events (all cause mortality, re-infarction, and heart failure admission).

Detailed Description

Pragmatic, controlled, prospective, randomized, open-label, blinded endpoint clinical trial testing the benefits of beta-blocker maintenance therapy in patients discharged after an acute myocardial infarction (MI). Patients being discharged after an acute MI, with or without ST-segment elevation, and with a left ventricular ejection fraction \>40%, and without history of heart failure (HF) prior to study inclusion, will be recruited. At discharge, patients will be randomized (1:1) to receive beta-blocker therapy (agent and dose according to treating physician) or no beta-blocker therapy. Primary outcome is the 5 years incidence of MACE (all cause mortality, reinfarction, heart failure admission).

Study Timeline

• Study First Submitted: 2018-06-15
• Study First Submitted QC: 2018-07-20
• Study First Posted: 2018-07-23
• Study Start: 2018-10-31
• Primary Completion: 2025-01-31
• Study Completion: 2025-01-31
• Status Verified: 2025-06
• Last Update Submitted: 2025-06-03
• Last Update Posted: 2025-06-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 8505

Inclusion Criteria

• ≥18 years old
• Admitted for STEMI or NSTEMI and invasive management (i.e. coronary angiography during index hospitalization).
• LVEF>40% as evaluated by any imaging technique anytime during hospitalization.
• Signed informed consent

Exclusion Criteria

• Known allergy or intolerance to beta-blockers
• Absolute contraindication to beta-blocker therapy according to treating physician judge
• Prior history of HF, Killip class on admission or during hospitalization ≥ II
• Severe valvular heart disease (> 3+ for aortic or mitral insufficiency, aortic or mitral valve area ≤1.0 cm2).
• Any condition (appart from AMI) that requires beta-blocker prescription on discharge according to treating physician judge
• Any medical condition that, in the investigator´s judgment, would seriously limit life expectancy (less than one year),
• Patients participating in other clinical trials

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Beta-blocker therapy	Beta blocker	This is a strategy (pragmatic) trial. In patients allocated to "Beta-blocker therapy", beta blocker agent and dose are decided by treating physician. betablocker therapy chosen might be any of the following: atenolol bisoprolol carvedilol metoprolol nebivolol

Primary Outcome Measures

Name	Time	Method
Incidence rate of the composite of "all-cause death, nonfatal reinfarction, or heart failure hospitalization" (MACE)	12-54 months since the beginning (median follow up anticipated 3.75 years)	absolute number of patients experiencing deaths will be added to number of patients experiencing a non fatal reinfarction and to number of patients experiencing heart failure hospitalization.; If a patient experience more than one of these events, only first event will be added for the sum of events; EXAMPLE events in arm 1: 150 deaths+150 reinfarctions+150 heart failure hospitalizations= TOTAL 450 MACE (450 events/4234 patients enroled: event rate 10.63%)

Secondary Outcome Measures

Name	Time	Method
2.1 Incidence rate of individual components of the primary outcome. 2.2 Incidence rate of cardiac mortality. 2.3 Incidence of sustained ventricular tachycardia/ventricular fibrillation (VT/VF) and resuscitated cardiac arrest.	12-54 months since the beginning (median follow up anticipated 3.75 years)	Absolute number of events (% from total patients recruited) of the components of the MACE (eg number of all cause deaths (% from patients included) in active arm vs control).; First event of each individual component counts for secondary outcome.; EXAMPLE all cause death events in in arm 1: 200 deaths (200 events/4234 patients enroled: event rate 4.72%).; nonfatal reinfarctions in in arm 1: 150 reinfarctions (150 events/4234 patients enroled: event rate 3.54%).; note that in the example of the primary outcome, only 150 deaths are counted and for the secondary outcome 200. This is because in this hypothetical case, 50 deaths occurred in patients who previously experienced a nonfatal reinfarction

Trial Locations

Locations (109)

Teresa Masselli Mascia; 🇮🇹 San Severo, Foggia, Italy

Ospedale Civile Santi Antonio e Biagio; 🇮🇹 Alessandria, Italy

Azienda Ospedaliero Universitaria Ospedali Riuniti; 🇮🇹 Ancona, Italy

Ospedale Civile; 🇮🇹 Baggiovara, Italy

Istituto Maugeri IRCCS; 🇮🇹 Bari, Italy

Ospedale San Paolo; 🇮🇹 Milano, Italy

Ospedale Maggiore; 🇮🇹 Bologna, Italy

A.O. Sant'Anna e San Sebastiano di Caserta; 🇮🇹 Caserta, Italy

Santa Margherita; 🇮🇹 Cortona, Italy

Ospedale di Cremona; 🇮🇹 Cremona, Italy

Scroll for more (99 remaining)